Clinical Trials

Phase 2 Active not recruiting

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04594798 2025-12-17

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

39 enrolled

Phase 1 Not yet recruiting

Lymphoma, B-Cell

NCT07270835 2025-12-08

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

Phase 4 Recruiting

40 enrolled

LymphoidMyeloid

Lymphoma, B-Cell, Lymphohistiocytosis, Hemophagocytic

NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

15 enrolled

Phase 1 Active not recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05270057 2025-10-09

LONCA

11 enrolled

Phase 1 Active not recruiting

Burkitt Lymphoma, Lymphoma, B-Cell

NCT04447716 2025-09-15

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

4 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT05950334 2025-08-22

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

20 enrolled

Lymphoma, B-Cell

NCT03424122 2025-08-21

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

50 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07081022 2025-08-21

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

180 enrolled

Phase 2 Active not recruiting

Lymphoma, B-Cell

NCT03505762 2025-08-20

Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

80 enrolled

Lymphoma, B-Cell

NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

17 enrolled 21 charts

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

NCT07073833 2025-07-18

The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma

Phase 1 Recruiting

40 enrolled

Phase 2 Active not recruiting

Lymphoma, B-Cell

NCT03995147 2025-06-08

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

51 enrolled

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06251180 2025-03-25

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

112 enrolled

Lymphoma, B-Cell

NCT01701986 2025-02-28

Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Phase 1/2 Completed

64 enrolled 13 charts

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, T-Cell

NCT01855750 2025-02-04

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Phase 3 Completed

838 enrolled 16 charts

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03467373 2025-01-17

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

111 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT05201248 2025-01-07

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

49 enrolled

Neoplasms, Lymphoma, B-Cell

NCT03307746 2024-12-02

RiVa

Phase 1/2 Completed

26 enrolled

Lymphoma, B-Cell

NCT03671018 2024-11-29

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

422 enrolled

Lymphoma, B-Cell

NCT04659044 2024-09-19

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Phase 2 Terminated

3 enrolled 11 charts

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02628405 2024-07-01

R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

30 enrolled 15 charts

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02564744 2024-06-12

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

Phase 2 Completed

100 enrolled 21 charts

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04220008 2024-01-12

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Phase 2 Withdrawn

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02733042 2023-11-18

FUSION NHL 001

Phase 1/2 Completed

106 enrolled 48 charts

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05929716 2023-11-13

An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma

Phase 2 Withdrawn

Lymphoma, B-Cell

NCT04023071 2023-10-26

FT516 in Subjects With Advanced Hematologic Malignancies

Phase 1 Terminated

72 enrolled

Lymphoma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell

NCT04245722 2023-10-26

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Phase 1 Terminated

98 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT03003546 2023-06-15

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

9 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04045028 2023-04-07

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1 Terminated

41 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphoma, B-Cell

NCT01238692 2023-03-24

A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)

Phase 2 Completed

42 enrolled